

MANAGING POSTOPERATIVE RECURRENCE IN DISTINCT MSI-H/HER2-NEGATIVE AND MSS/HER2-POSITIVE ADVANCED GASTRIC CANCERS WITH PTCD PLACEMENT

Norio Kanzaki

UEG Week Copenhagen 2023

Poster

Oesophagus

October 15, 2023

A case report describes the management and recurrence of synchronous advanced gastric cancers with distinct molecular profiles, one HER2-positive MSS and one HER2-negative MSI-H, in a 59-year-old male.

KEY POINTS

- Two distinct advanced gastric carcinomas were identified with different molecular characteristics: the upper lesion was HER2-positive and MSS while the lower-middle lesion was HER2-negative and MSI-H
- The patient underwent preoperative chemotherapy with S-1 and CDDP followed by total gastrectomy with D2 dissection and postoperative adjuvant chemotherapy with DOC and S-1
- Recurrence occurred as intrahepatic metastasis at the hepatic duct confluence presenting with rapid jaundice progression after the 10th course of adjuvant therapy
- Treatment with FOLFOX and nivolumab after PTCD insertion resulted in significant tumor shrinkage allowing PTCD removal with ongoing treatment
- The case illustrates challenges in managing multiple synchronous gastric cancers with heterogeneous molecular profiles and discusses treatment approaches for recurrent disease

VIEW THIS CONTENT ON GUTFLIX

<https://gutflrx.eu/search/d/2c1204ee-743d-11ee-8e71-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.